Number_reference_aid_programme: SA.41471(2015/X) Purpose of public aid: Article 25 of Regulation (EC) No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with the internal market in the application of Articles 107 and 108 of the Treaty That’s it. EU L 187/1 of 26.06.2014). The aim of the project implemented by the Consortium consisting of the Research and Development Centre Novasome Sp. z o.o. (leader) and Pikralida Sp. z o.o. is to develop technological innovation and its verification in real conditions on the pilot line kilo-lab, enabling effective, safe and flexible synthesis of pharmaceutical active substances (API). The new technology will be developed on the basis of the model route of API synthesis — tadalafil. The implementation of innovations will help maintain the stability of supply chains and access to medicines, in line with medical guidelines for all patients in need. The technological innovation created as part of the Project will allow for further research on the processes of producing a wide range of APIs in an efficient and flexible way. The developed processes will be optimised in terms of materials, cost and environment. The project will be implemented in the period 01.07.2021-31.12.2023 as part of 5 stages of R & D. The implementation of the project in a consortium of a large entity and SMEs will be a unique example of mutual knowledge transfer and will allow for optimal use of the competences of both research teams. The results of the Project will be implemented in Poland within 3 years from the completion of the Project, and the results will constitute an important know-how, which is the basis for the implementation of further advanced research projects, thus contributing to the development of the domestic pharmaceutical sector. The result of the project responds to the needs of the national and EU pharmaceutical sector and is part of the current Pharmaceutical Strategy for Europe, including increasing the production capacity of medicines and APIs in the EU.